Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 2/20 | 0.34 |
| ▸ | MMP13 | P45452 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | IKBKB | O14920 | 9/20 | 0.32 |
| ▸ | CHUK | O15111 | 9/20 | 0.32 |
| ▸ | F10 | P00742 | 1/20 | 0.31 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
| ▸ | HTR7 | P34969 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2981796 | 0.95 | MMP1 (0.32) | MMP1MMP13F10 | |
| SCHEMBL2980033 | 0.93 | IKBKB (0.39) | MMP1MMP13HPGDSMN1; SMN2IKBKB | |
| SCHEMBL2981793 | 0.90 | KMT2A (0.38) | IKBKBCHUK | |
| SCHEMBL2987892 | 0.90 | IKBKB (0.38) | MMP1MMP13HPGDSMN1; SMN2IKBKB | |
| SCHEMBL3415802 | 0.85 | IKBKB (0.46) | IKBKBCHUKHTR1AHTR7 | |
| SCHEMBL2985375 | 0.83 | IKBKB (0.47) | IKBKBCHUKHTR1AHTR7 | |
| SCHEMBL2987895 | 0.82 | IKBKB (0.45) | HPGDSMN1; SMN2IKBKBCHUKMAP3K5 | |
| SCHEMBL3415349 | 0.81 | IKBKB (0.42) | IKBKBCHUKHTR1AHTR7 | |
| SCHEMBL13241054 | 0.80 | PTGDR2 (0.36) | MAP3K5 | |
| SCHEMBL2980723 | 0.79 | MAP3K5 (0.52) | IKBKBCHUKMAP3K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179139-A1 | PYRROLOPYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | BAMBOROUGH PAUL | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179139-A1 | PYRROLOPYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | NFKBIA, PACSIN2, MAP3K2 | MMP1 3392/4885MMP13 4694/4885HPGD 930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.